Global /United States /Healthcare /Drug Manufacturers - General /LIMN

Liminatus Pharma, Inc.

LIMN

• NASDAQ: LIMN • Delayed

0.2044USD 0.3%

As of 13 June 2026, Liminatus Pharma, Inc. has a market cap of $9.17M USD, ranking #41740 globally and #5381 in the United States. It ranks #3697 in the Healthcare sector, and #1201 in the Drug Manufacturers - General industry.

Global Rank

41740

Country Rank

5381

Sector Rank

3697

Industry Rank

1201

Key Stats

Market Cap

$9.17MUSD

Enterprise Value

$10.24MUSD

EBITDA (TTM)

-$2.97MUSD

Net Income (TTM)

-$10.21MUSD

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Chris Kim open_in_new

Employees

Founded

2018

Website

liminatuspharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.3%	-1.3%	8.6%	-67%	-86%	-67%	-96%	-98%	-99%

News

LIMN Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	LIMN Liminatus Pharma Inc Class A Ordinary Shares ISIN: US53271X1081 Shares Out.: Shares Outstanding: 44.878M¹ Shares Float: 23.368M² TV: TradingView: NASDAQ: LIMN SA: Stock Analysis: NASDAQ: LIMN YF: Yahoo Finance: LIMN GF: Google Finance: NASDAQ: LIMN NQ: NASDAQ: LIMN BA: Barron's: LIMN MS: Morningstar: XNAS: LIMN	0.2044 USD	TV: TradingView: NASDAQ: LIMN SA: Stock Analysis: NASDAQ: LIMN YF: Yahoo Finance: LIMN GF: Google Finance: NASDAQ: LIMN NQ: NASDAQ: LIMN BA: Barron's: LIMN MS: Morningstar: XNAS: LIMN

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 8M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 6M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 4M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 3M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 2M%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 1M%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 4M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 3M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 3M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 2M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 1M%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 1M%	14.6	United Kingdom

chevron_leftBack